{"id":"rabbit-atg-genzyme","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Fever"},{"rate":"50-70","effect":"Chills"},{"rate":"40-60","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Leukopenia"},{"rate":"10-30","effect":"Serum sickness"},{"rate":"20-40","effect":"Infection"},{"rate":"20-30","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabbit ATG is derived from immunized rabbits and contains polyclonal antibodies against human T-cell antigens. It binds to circulating and tissue-resident T cells, leading to their elimination through complement activation and antibody-dependent cell-mediated cytotoxicity. This profound immunosuppression is used to prevent graft rejection and treat T-cell mediated conditions.","oneSentence":"Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:36.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in renal transplantation"},{"name":"Treatment of acute rejection episodes in transplant recipients"},{"name":"Aplastic anemia"}]},"trialDetails":[{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT06374095","phase":"","title":"1 vs 7 RATG Infusions in Renal Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-07-30","conditions":"Kidney Replacement","enrollment":75},{"nctId":"NCT06108739","phase":"PHASE3","title":"ATG Plus Low-dose PT-Cy for GVHD Prevention","status":"TERMINATED","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"Hematologic Malignancy","enrollment":66},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06198842","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-11-22","conditions":"Nijmegen Breakage Syndrome","enrollment":10},{"nctId":"NCT00471848","phase":"PHASE2","title":"Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2008-08","conditions":"Aplastic Anemia","enrollment":35},{"nctId":"NCT02745717","phase":"PHASE4","title":"The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT00603954","phase":"PHASE2","title":"Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings","status":"COMPLETED","sponsor":"University of Liege","startDate":"2008-01","conditions":"Hematological Malignancies","enrollment":107},{"nctId":"NCT01104025","phase":"PHASE2","title":"Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":31},{"nctId":"NCT04400045","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2020-05-22","conditions":"Nijmegen Breakage Syndrome","enrollment":10},{"nctId":"NCT00709592","phase":"PHASE2","title":"Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2008-07-21","conditions":"Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma","enrollment":42},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT00863148","phase":"PHASE2","title":"Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2009-10","conditions":"MDS, AML, ALL","enrollment":30},{"nctId":"NCT02676622","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Refractory Crohn's Disease","status":"WITHDRAWN","sponsor":"Nationwide Children's Hospital","startDate":"2013-04","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02838992","phase":"PHASE4","title":"ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Jinan Military General Hospital","startDate":"2017-02","conditions":"Aplastic Anemia","enrollment":130},{"nctId":"NCT02784561","phase":"PHASE4","title":"Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-07","conditions":"Leukemia","enrollment":80},{"nctId":"NCT01530555","phase":"PHASE2","title":"Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2008-04","conditions":"Acquired Aplastic Anaemia","enrollment":35},{"nctId":"NCT00782821","phase":"PHASE4","title":"Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-09","conditions":"Kidney Transplantation","enrollment":40},{"nctId":"NCT00861536","phase":"PHASE4","title":"Comparison of ATG to Thymoglobuline in Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-01","conditions":"Transplantation, Kidney","enrollment":40},{"nctId":"NCT00038857","phase":"PHASE2","title":"Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-09","conditions":"Leukemia, Lymphoma","enrollment":29},{"nctId":"NCT00915811","phase":"PHASE2","title":"Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2007-06","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute","enrollment":20},{"nctId":"NCT00682292","phase":"PHASE3","title":"Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2001-05","conditions":"Renal Transplantation","enrollment":227}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thymoglobuline","Anti-thymoeyteGlobulin"],"phase":"marketed","status":"active","brandName":"Rabbit ATG, (Genzyme)","genericName":"Rabbit ATG, (Genzyme)","companyName":"Jinan Military General Hospital","companyId":"jinan-military-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity. Used for Prevention of acute organ rejection in renal transplantation, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}